Literature DB >> 8593253

Stereoselective disposition of hydroxychloroquine and its metabolite in rats.

Y Wei1, G A Nygard, S L Ellertson, S K Khalil.   

Abstract

Racemic hydroxychloroquine-sulfate (HCQ-sulfate) was administered to rats orally. Groups of 9 male and 9 female rats received doses of 0, 8, 16, or 24 mg/kg/day for 6 weeks, followed by a reduction of the higher doses to 8 mg/kg/day for the duration of the study. Whole blood samples were collected at 0, 3, 6, 8, and 10 weeks, and eleven tissues were harvested after the tenth week. The concentrations and enantiomer ratios of the parent drug and three metabolites, desethylhydroxychloroquine (DHCQ), desethylchloroquine (DCQ), and bisdesethylchloroquine (BDCQ), were determined. The highest concentration of HCQ was found in the intestinal smooth muscle, and the lowest in the brain and adipose tissue. The highest concentrations of the metabolites were found in the liver, adrenals, and lung tissue. The metabolism of HCQ in the rats was found to be stereoselective with R/S > 1 for the drug and < 1 for the metabolites. Gender-specific differences in the proportions of the drug and its metabolites and their enantiomers in blood and tissue were found. Varying dosages appeared to have only a temporary influence on blood concentrations and not to effect the enantiomer ratios in blood. Only a limited number of tissues exhibited significant differences between dose groups. There were no observed differences in enantiomer ratios among the blood collection times.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8593253     DOI: 10.1002/chir.530070807

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  7 in total

1.  Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation.

Authors:  Keagan P Collins; Kristen M Jackson; Daniel L Gustafson
Journal:  J Pharmacol Exp Ther       Date:  2018-02-08       Impact factor: 4.030

Review 2.  Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis.

Authors:  Heather Y F Yong; V Wee Yong
Journal:  Nat Rev Neurol       Date:  2021-11-03       Impact factor: 42.937

Review 3.  Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs.

Authors:  Dion R Brocks; Reza Mehvar
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.

Authors:  Suzanne J F Kaptein; Sofie Jacobs; Lana Langendries; Laura Seldeslachts; Sebastiaan Ter Horst; Laurens Liesenborghs; Bart Hens; Valentijn Vergote; Elisabeth Heylen; Karine Barthelemy; Elke Maas; Carolien De Keyzer; Lindsey Bervoets; Jasper Rymenants; Tina Van Buyten; Xin Zhang; Rana Abdelnabi; Juanita Pang; Rachel Williams; Hendrik Jan Thibaut; Kai Dallmeier; Robbert Boudewijns; Jens Wouters; Patrick Augustijns; Nick Verougstraete; Christopher Cawthorne; Judith Breuer; Caroline Solas; Birgit Weynand; Pieter Annaert; Isabel Spriet; Greetje Vande Velde; Johan Neyts; Joana Rocha-Pereira; Leen Delang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-09       Impact factor: 11.205

5.  Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment.

Authors:  Yan Wang; Lei Chen
Journal:  Eur J Pharmacol       Date:  2020-10-06       Impact factor: 4.432

6.  Biomimetic properties and estimated in vivo distribution of chloroquine and hydroxy-chloroquine enantiomers.

Authors:  Klara L Valko; Tong Zhang
Journal:  ADMET DMPK       Date:  2020-01-25

7.  Lysosomal Biogenesis and Implications for Hydroxychloroquine Disposition.

Authors:  Keagan P Collins; Sandra Witta; Jonathan W Coy; Yi Pang; Daniel L Gustafson
Journal:  J Pharmacol Exp Ther       Date:  2020-11-10       Impact factor: 4.030

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.